Please login to the form below

Not currently logged in
Email:
Password:

Alexion Pharmaceuticals adds to its board

Judith Reinsdorf recently worked at Johnson Controls

Alexion Pharmaceuticals has appointed Judith Reinsdorf to its board of directors following her role as executive vice president and general counsel of Johnson Controls.

Reinsdorf, who has a background in corporate governance and expertise in managing corporate and legal affairs, has served in various positions for companies including Tyco International and Monsanto.

David Brennan, chairman of the board, said: “We are pleased to welcome Judy to Alexion’s board of directors.

“She brings strong corporate governance and legal expertise, with a proven track records in global compliance, strategic planning, data privacy and regulatory matters.

“Her broad experience at large US public companies, both within and outside the healthcare industry, will be a valuable addition to our board.”

Reinsdorf joins at a time when the company aims to “strengthen its leadership position in rare diseases”.

She said: “I am excited to join Alexion’s board of directors at a pivotal time for the company as it executes its strategy to deliver sustainable growth and I look forward to applying my experience to help guide Alexion’s future success.”

In addition, director Ann Veneman has also announced that she does not plan to stand for re-election as she will be retiring following eight years of service.

5th March 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....